TRV GP Iv, LLC

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 13, 2024), TRV GP Iv, LLC reported 3 stock positions worth $206.4 million. Its top holding was Tango Therapeutics (TNGX) at 73.9% of the portfolio, followed by Pliant Therapeutics (PLRX, 15.4%) and Fulcrum Therapeutics (FULC, 10.7%). Compared with Q4 2023, it reduced 1. The biggest sale was Tango Therapeutics (TNGX, shares −1%).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$206.4M (Q1 2024)
SEC Filing
0000950123-24-004644 ↗ filed May 13, 2024

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 3 stocks · $206.4M
TNGX Tango Therapeutics Inc. 73.88% 19,201,475 $152.5M Reduce -0.8%
PLRX Pliant Therapeutics Inc. 15.40% 2,132,867 $31.8M No change
FULC Fulcrum Therapeutics Inc. 10.72% 2,343,154 $22.1M No change

Portfolio Sells Q4 2023 → Q1 2024
TNGX Tango Therapeutics Inc. Reduce -0.8% 73.88% −4.00

Portfolio Buys Q4 2023 → Q1 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC